A federal bankruptcy judge has made a landmark decision to approve a historic multi-billion-dollar opioid settlement involving OxyContin-maker Purdue Pharma and its owners, the Sackler family. This decision marks a significant development in the nationwide litigation over the opioid epidemic, providing a crucial step forward in the legal battle.
The latest settlement requires the Sackler family to relinquish ownership of Purdue Pharma and contribute up to $7 billion over the next 15 years, a move negotiated after the U.S. Supreme Court rejected an earlier draft that would have protected the family from future lawsuits. The new plan allows entities that do not opt into the settlement to continue seeking legal action against the Sacklers, ensuring they do not receive blanket immunity from civil suits.
Most of the settlement funds will be directed toward state, local, and Native American tribal governments, supporting initiatives to mitigate the impact of the opioid crisis by funding addiction treatment, prevention, and recovery resources. A substantial portion, nearly $865 million, will also be allocated to individual victims of opioid addiction.
Bankruptcy Judge Sean Lane, who presided over the proceedings, described the case as one of the most complex bankruptcies in U.S. history. He emphasized the near-unanimity among attorneys representing governments, tribes, victims, and other parties, all urging approval of the plan as the most practical way to resolve the vast and complicated claims, some totaling in the trillions of dollars.
While some objectors voiced concerns that only victims, rather than government entities, should receive compensation and that the settlement does not impose criminal liability on the Sackler family, Lane made clear that his authority is limited to civil claims. Importantly, prosecutors can still pursue criminal charges separately: the settlement does not prevent this.
The approval of the settlement will close a significant chapter in opioid litigation that has seen more than 900,000 U.S. deaths since 1999. The company will undergo a name change to Knoa Pharma, with oversight transferred to a new board dedicated to using profits to combat the ongoing opioid crisis. According to government representatives, the funds delivered by the settlement are already contributing to a decrease in overdose deaths in recent years, offering hope for a brighter future.
If finalized, the Purdue Pharma and Sackler settlement will rank among the largest of its kind, both in terms of damages awarded and the scope of victims covered, signifying a step toward justice and healing for communities devastated by opioid addiction.
Sources:
https://www.cdc.gov/overdose-prevention/about/understanding-the-opioid-overdose-epidemic.html
https://addictiongap.org/opioid-overdose-data
